Associated Papers
Clonal hematopoiesis associates with prevalent and incident cardiometabolic disease in a cardiac catheterization cohort.
Regan JA et al.
Plos One, 2026
Ancestry-dependent patterns of somatic mosaicism and clonal hematopoiesis mutations in over 125,000 individuals reveal distinct cancer associations.
Colin-Leitzinger C et al.
Human Genomics, 2025
Clonal hematopoiesis in apparent treatment-resistant hypertension, insights from multiple medical centers and community-based cohorts.
Lv C et al.
Nature Aging, 2025
Distinct characteristics of lymphoid and myeloid clonal hematopoiesis in World Trade Center first responders.
Esai Selvan M et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Clonal Hematopoiesis of Indeterminate Potential Is Associated With Incident Abdominal Aortic Aneurysm.
Tan Y et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2025
Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes.
Hiitola E et al.
Science Advances, 2025
Peripheral blood somatic mosaicism and clonal hematopoiesis across ancestry backgrounds.
Colin-Leitzinger C et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
Comparative analysis of the Mexico City Prospective Study and the UK Biobank identifies ancestry-specific effects on clonal hematopoiesis.
Wen S et al.
Nature Genetics, 2025
Clonal Hematopoiesis Associates with Prevalent and Incident Cardiometabolic Disease in High-Risk Individuals.
Regan JA et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis.
Zuriaga MA et al.
European Heart Journal, 2024
Rare variant associations with plasma protein levels in the UK Biobank.
Dhindsa RS et al.
Nature, 2023
Genetic modification of inflammation- and clonal hematopoiesis-associated cardiovascular risk.
Yu Z et al.
The Journal of Clinical Investigation, 2023
Clonal hematopoiesis is associated with protection from Alzheimer's disease.
Bouzid H et al.
Nature Medicine, 2023
IDH1 mutation activates mTOR signaling pathway, promotes cell proliferation and invasion in glioma cells.
Avsar T et al.
Molecular Biology Reports, 2022
Cancer-driving mutations are enriched in genic regions intolerant to germline variation.
Vitsios D et al.
Science Advances, 2022
Maffucci syndrome complicated by giant chondrosarcoma in the left ankle with an IDH1 R132C mutation: a case report.
Lv H et al.
World Journal of Surgical Oncology, 2022
Sequence Neighborhoods Enable Reliable Prediction of Pathogenic Mutations in Cancer Genomes.
Banerjee S et al.
Cancers, 2021
Inherited causes of clonal haematopoiesis in 97,691 whole genomes.
Bick AG et al.
Nature, 2020
Germline susceptibility variants impact clinical outcome and therapeutic strategies for stage III colorectal cancer.
Lin PC et al.
Scientific Reports, 2019
Isocitrate Dehydrogenase 1 Expression in Canine Gliomas.
Fraser AR et al.
Journal of Comparative Pathology, 2018
Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas.
Mito JK et al.
The American Journal of Surgical Pathology, 2018
Clinical prognostic value of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in glioblastoma.
Mistry AM et al.
Journal of Neuro-oncology, 2018
Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma.
Lu VM et al.
Cns Oncology, 2018
The distinct clinical features of giant cell tumor of bone in pagetic and non-pagetic patients are associated with genetic, biochemical and histological differences.
Divisato G et al.
Oncotarget, 2017
Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
Li J et al.
Molecular Medicine Reports, 2015
Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas.
Arita H et al.
Brain Tumor Pathology, 2015
Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Liu X et al.
Cancer Medicine, 2013
Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
Agarwal S et al.
Neuro-oncology, 2013
What do we know about IDH1/2 mutations so far, and how do we use it?
Horbinski C
Acta Neuropathologica, 2013
IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
Yang H et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
IDH mutations in human glioma.
Kim W et al.
Neurosurgery Clinics of North America, 2012
Role of isocitrate dehydrogenase in glioma.
Alexander BM et al.
Expert Review of Neurotherapeutics, 2011
IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
Zou Y et al.
Biochemical and Biophysical Research Communications, 2010
A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations.
Chou WC et al.
Blood, 2010
Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Gravendeel LA et al.
Human Mutation, 2010